Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript

Core Insights - Belite Bio presented topline data from its Phase III trial of Tinlarebant for Stargardt disease, known as the DRAGON study, which is the largest interventional trial conducted in adolescent patients with this condition [2] Group 1: Study Overview - The DRAGON study is a pivotal 2-year trial focusing on the efficacy of Tinlarebant in treating Stargardt disease [2] - The trial involved a significant number of adolescent patients, highlighting its scale and importance in the field of retinal diseases [2] Group 2: Leadership and Expertise - The conference call featured key executives from Belite Bio, including Dr. Tom Lin (Chairman and CEO) and Dr. Hendrik Scholl (Chief Medical Officer), who provided insights into the study [4] - Dr. Hendrik Scholl, a notable figure in retinal disease research, served as the coordinating principal investigator for the ProgStar Study, adding credibility to the DRAGON study [4]